T2DM/CKD genetic risk scores and the progression of diabetic kidney disease in T2DM subjects
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Genetic risk scores do not predict diabetic kidney disease progression better than clinical factors in type 2 diabetes patients. Current clinical assessments remain essential for predicting diabetic kidney disease, cardiovascular events, and mortality.
Area Of Science
- Nephrology
- Genetics
- Endocrinology
Background
- Diabetic kidney disease (DKD) is a major complication of type 2 diabetes mellitus (T2DM).
- Predicting DKD progression and related adverse outcomes like major cardiovascular events (MCVE) and all-cause mortality (ACM) is crucial for patient management.
- Genetic risk scores (GRS) are being explored as potential tools for personalized medicine in T2DM.
Purpose Of The Study
- To evaluate the predictive potential of GRS for DKD progression in T2DM patients.
- To assess GRS association with secondary outcomes: MCVE and ACM.
- To compare the predictive performance of GRS against established clinical factors.
Main Methods
- A cohort of 400 central European T2DM patients was analyzed.
- Thirty single nucleotide polymorphisms (SNPs) derived from T2DM and chronic kidney disease (CKD) Genome-Wide Association Studies (GWAS) were genotyped.
- Univariate Cox regression was used to assess associations between clinical variables, SNPs, and outcomes. GRS performance was evaluated using Area Under the Curve (AUC).
Main Results
- Clinical factors like age, diabetes duration, blood pressure, cholesterol, and eGFR significantly predicted DKD progression.
- No single SNP was conclusively associated with DKD progression; CERS2 and SHROOM3 showed borderline significance.
- One SNP (WSF1) associated with MCVE, and three SNPs (CANCAS1, CERS2, C9) associated with ACM.
- GRS did not improve prediction of DKD, MCVE, or ACM compared to clinical factors alone. The AUC difference (0.063) was not statistically significant (P=0.06).
Conclusions
- Current clinical factors are more predictive of DKD progression, MCVE, and ACM than GWAS-derived GRS in this T2DM cohort.
- The combination of genetic and clinical factors did not significantly enhance predictive accuracy.
- Further research is needed to identify robust genetic markers and understand their complex interplay with clinical factors for DKD prediction.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...